

**Amendments to the Specification**

Please replace the second full paragraph on page 4 with the following, amended paragraph:

According to a first aspect, the invention is directed to a GHRH analogue, a derivative of said analogue, or a pharmaceutically acceptable salt thereof comprising formula X: Tyr-A2-Asp-Ala-Ile-Phe-Thr-A8-A9-A10-Arg-Lys-Val-Leu-A15-Gln-Leu-Ser-Ala- Arg-A21-A22-Leu-Gln-Asp-Ile-Met-Ser-Arg-A30-NH<sub>2</sub>, wherein

A2 is Ala or D-Ala;

A8 is Asn, D-Asn or Ala;

A9 is Ser or Ala;

A10 is Tyr or D-Tyr;

A15 is Gly, Ala or D-Ala;

A21 is Lys or D-Lys;

A22 is Leu, D-Leu, Lys or Ala; and

A30 is a bond or any amino acid sequence of 1 up to 15 residues (SEQ ID NO. 65);

said analogue, derivative of said analogue or salt thereof having an in vitro potency index substantially higher than the in vitro potency index of a naturally occurring GHRH.

Please replace the second full paragraph on page 6 with the following, amended paragraph:

According to the first aspect, the present invention relates to a GHRH analogue, a functional derivative or a pharmaceutically acceptable salt thereof. More specifically, the GHRH analogue of the invention has an amino acid sequence comprising the following Formula X: Tyr-A2-Asp-Ala-Ile-Phe-Thr-A8-A9-A10-Arg-Lys-Val-Leu-A15-Gln-Leu-Ser-Ala-Arg-A21-A22-Leu-Gln-Asp-Ile-Met-Ser-Arg-A30-NH<sub>2</sub>, and wherein A2 is Ala or D-Ala; A8 is Asn, D-Asn or Ala; A9 is Ser or Ala; A10 is Tyr or D-Tyr; A15 is Gly, Ala or D-Ala; A21 is Lys or D-Lys; and A22 is

Leu, D-Leu, Lys or Ala, and A30 is a bond or any amino acid sequence of 1 up to 15 residues (SEQ ID NO. 65). The term "residue", when used with reference to an amino acid, means a radical derived from the corresponding amino acid by eliminating the hydroxyl of the carboxyl group and one hydrogen of the amino group.

Please replace the first full paragraph on page 8 with the following, amended paragraph:

According to the present invention, different combinations of polysubstitutions in the native form of GHRH are preferred. Accordingly, in one such combination, a preferred GHRH analogue comprises the above-mentioned Formula X with the following substitutions: A2 is D-Ala, A8 is Ala, A15 is Ala, A22 is Lys[[.]], and A9, A10, A21 and A30 are as defined hereinabove.

Please replace the second full paragraph on page 8 with the following, amended paragraph:

Another preferred analogue of the present invention comprises Formula X wherein A2 is D-Ala, A10 is D-Tyr, and A22 is Lys[[.]], and A8, A9, A15, A21 and A30 are as defined hereinabove.

Please replace the third full paragraph on page 8 with the following, amended paragraph:

According to yet another preferred analogue of the present invention, said analogue comprises Formula X wherein A2 is D-Ala, A10 is D-Tyr, A15 is D-Ala and A22 is Lys[[.]], and A8, A9, A21 and A30 are as defined hereinabove.